With regard to safety and tolerability, the study showed no evidence of increased intraocular pressure or inflammatory response to treatment. MacuSight intends to complete its collection and analysis of all data from this trial and present final findings later this year.
"From a patient treatment standpoint, the study findings related to the safety and biological activity of sirolimus administered through subconjunctival injection are very exciting," stated Pravin U. Dugel, M.D., clinical instructor, vitreoretinal diseases and surgery, department of ophthalmology, University of Arizona, partner at Retinal Consultants of Arizona in Phoenix, Arizona, and the study's lead investigator. "By offering both physicians and patients significant benefits in the way of reduced invasiveness, safety and ease of administration, the subconjunctival injection has the potential to dramatically improve the current DME treatment paradigm."
Additionally, MacuSight has completed enrollment of its second Phase 1 trial which is examining its same proprietary sirolimus formulation in patients with exudative age-related macular degeneration. Results from this second trial are expected to be presented during the first half of 2008.
Sirolimus, originally known as rapamycin, is a highly-potent,
broad-acting compound that has demonstrated the ability to combat disease
through multiple mechanisms of action including immunosuppressive,
anti-angiogenic, anti-migratory, anti-proliferative, anti-fibrotic and
anti-permeability activity. Based on the versatility associated with these
multiple mechanisms of action, MacuSight
|SOURCE MacuSight, Inc.|
Copyright©2007 PR Newswire.
All rights reserved